On March 13, 2018NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, reported that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018 (Press release, NantKwest, MAR 13, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2337947 [SID1234524736]). The presentations and one-on-one discussions will feature a science and business overview, along with a clinical update provided by company management.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:
Event: Roth Capital 30th Annual Investment Conference
Date/Time: Tuesday, March 13, 2018, one-on-one meetings
Location: Laguna Niguel, CA

Event: Cowen & Company 38th Annual Healthcare Conference
Date/Time: Wednesday, March 14, 2018, one-on-one meetings
Location: Boston, MA

Event: Oppenheimer & Company 28th Annual Healthcare Conference
Date/Time: Tuesday, March 20, 2018, one-on-one meetings
Location: New York, NY

Event: Needham & Company 17th Annual Healthcare Conference
Date/Time: Wednesday, March 28, 2018, presentation at 12:45pm
Location: New York, NY

Event: Hanson Wade Innate Killer Summit
Date/Time: Thursday, March 29, 2018, presentation at 12:50pm
Location: New York, NY

Event: Jefferies IO Cell Therapy Investment Conference
Date/Time: Tuesday, April 3, 2018, presentation at 11:40am
Location: Boston, MA

On March 13, 2018 Actinium Pharmaceuticals reported that the Medical College of Wisconsin received clearance from the U.S. Food and Drug Administration (FDA) for the previously announced Investigational New Drug (IND) application for the Phase 1 trial of Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia (AML) patients (Press release, Actinium Pharmaceuticals, MAR 13, 2018, View Source [SID1234524720]). This investigator initiated trial will be conducted at the Medical College of Wisconsin and led by principal investigator Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah. This trial will enroll up to 18 patients and will assess safety as well as efficacy, which will be based on response rates, percentage of patients receiving a bone marrow transplant and overall survival. Actimab-A is an antibody radio-conjugate (ARC) that combines the anti-CD33 antibody lintuzumab with the radioisotope actinium-225. CLAG-M is a salvage chemotherapy regimen consisting of cladribine, cytarabine, filgrastim and mitoxantrone that has become the standard of care at many institutions across the U.S. in AML patients with relapse.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mark Berger, Actinium’s Chief Medical Officer said, "The use of our actinium-225 – anti-CD33 ARC in combination with cytotoxic therapies such as CLAG-M has the potential to improve outcomes for a significant number of patients. We believe our ARC approach, which has shown to be potent while having minimal extramedullary toxicities in over 100 patients to date, has the potential to be synergistic with cytotoxic chemotherapy agents. CLAG-M has shown compelling results in patients with relapsed or refractory disease and we believe that the combination with our ARC can improve response rates, transplant rates and overall survival for patients. We are excited to begin enrolling patients on this trial and look forward to working with Dr. Abedin, Dr. Atallah and their colleagues at the Medical College of Wisconsin on this important Phase 1 study."

This Phase 1 combination trial is the fourth clinical trial from Actinium’s CD33 program. The Company’s other CD33 program trials include its Phase 2 trial Actimab-A trial for patients newly diagnosed with AML who are over the age of 60 and unfit for intense chemotherapy and the Phase 1 Actimab-M trial for patients with refractory multiple myeloma. A Phase 2 trial is planned for patients with high-risk myelodysplastic syndrome with a p53 genetic mutation for myeloablation prior to a bone marrow transplant.

Sandesh Seth, Actinium’s Chairman and CEO said, "We see the use of our ARC’s in combination with chemotherapy as an exciting development opportunity that has the potential to bring benefits to a significant number patients. We believe that this will be the first of many combinations given the potency of our ARC approach together with its minimal extramedullary toxicities and its unique mechanism of action. Together these attributes make our ARC a versatile therapy that we believe can bring benefits to patients as a monotherapy, in combination and for myeloablation prior to a bone marrow transplant."

About Actimab-A

Actimab-A is Actinium’s lead drug candidate from its CD33 program and is an antibody radio-conjugate (ARC) that is comprised of the CD33 targeting antibody lintuzumab and actinium-225, an alpha-emitting radioisotope. This ARC is currently being studied in the Phase 2 Actimab-A is clinical trial in patients that are newly diagnosed with AML who are over the age of 60 that are ineligible for intense chemotherapy, also known as unfit patients. Actimab-A has been granted Orphan Drug Designation for newly diagnosed AML in patients 60 and above by the U.S. Food and Drug Administration and the European Medicines Agency. The Company is also conducting the Phase 1 Actimab-M trial, an investigator initiated trial for patients with refractory multiple myeloma. Also, Actinium plans to begin the Phase 2 Actimab-MDS trial for patients with high-risk myelodysplastic syndrome (MDS) that have a p53 genetic mutation myeloablation prior to a bone marrow transplant. Actimab-A is a second-generation therapy from the Company’s CD33 Program, which was developed at Memorial Sloan Kettering Cancer Center and has now been studied in over 100 patients in four clinical trials.

On March 13, 2018 Pfenex Inc. (NYSE AMERICAN: PFNX), reported that the company will present at Oppenheimer’s 28th Annual Healthcare Conference in New York City (Press release, Pfenex, MAR 13, 2018, View Source2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference" target="_blank" title="View Source2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference" rel="nofollow">View Source [SID1234524737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

President and Chief Executive Officer, Eef Schimmelpennink, is scheduled to present on Tuesday, March 20, 2018 from 4:30 PM – 5:00 PM ET in the Track 2 room.

Interested parties can access the live audio webcast for this presentation from the Investors Section of Pfenex’s website at www.pfenex.com. The webcast replay will be available after the conclusion of the live presentation for approximately 60 days.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

On 13 March, 2018 Boehringer Ingelheim and Vanderbilt University reported the expansion of their successful existing collaboration to develop novel anti-cancer compounds (Press release, Boehringer Ingelheim, MAR 13, 2018, View Source [SID1234524727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third collaboration between Boehringer Ingelheim and Vanderbilt University to pursue discoveries made in the laboratory of Stephen W. Fesik, Ph.D., at Vanderbilt University School of Medicine.

"Boehringer Ingelheim and Vanderbilt University have the expertise and are jointly focused on discovering breakthrough medicines against the cancer causing proteins KRAS, SOS and now, MCL1," said Darryl McConnell, Ph.D., Vice President and Research Site Head, Boehringer Ingelheim, Austria. "Together, we are committed to driving scientific research and development forward to help patients win the fight against cancer."

"MCL1 is one of the top ten overexpressed genes in human cancer where it plays a role as a survival factor," said Lawrence J. Marnett, Ph.D., Dean of Basic Sciences in the Vanderbilt University School of Medicine.

"It is a great target for therapy but candidate drugs need to disrupt high affinity protein-protein interactions, which is very challenging," Marnett said. "The Fesik laboratory has made impressive strides in developing such compounds and it is exciting to see them advanced toward clinical development through the partnership with Boehringer Ingelheim."

MCL1, when overexpressed, can prevent cancer cells from undergoing programmed cell death (also known as apoptosis). This necessitates the discovery of a molecule that binds extremely tightly and selectively to MCL1 in order to sufficiently induce on-target, mechanism-based cancer cell death.

"Boehringer Ingelheim has an outstanding oncology drug discovery infrastructure that brings various research and development groups together to tackle challenging cancer targets," said Fesik, Professor of Biochemistry, Pharmacology, and Chemistry at Vanderbilt. "In combination with our multidisciplinary team of structural biologists, medicinal chemists and cell biologists, we will work to search for anti-cancer compounds that inhibit MCL1 in order to tackle this complex area of unmet medical need."

Boehringer Ingelheim is steadfast in its partnership with Vanderbilt University and is deeply committed to delivering breakthrough, first-in-class treatments to help cancer patients everywhere, despite the challenges that may present themselves. This agreement between Boehringer Ingelheim and Vanderbilt University includes undisclosed upfront and milestone payments, with the ambition of delivering a new cancer drug to market as quickly as possible.

About Boehringer Ingelheim in Oncology
Cancer takes. Takes away loved ones, time and untapped potential. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.

On March 13, 2018 – Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a
clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for patients with solid tumor cancers, reported that
James F. Oliviero, President and Chief Executive Officer, will participate in two investor conferences in
March (Press release, Checkpoint Therapeutics, MAR 13, 2018, View Source [SID1234525086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• Oppenheimer’s 28th Annual Healthcare Conference: Checkpoint will host one-on-one meetings
on Wednesday, March 21, 2018, at the Westin New York Grand Central in New York City
• The Wall Street Investor Forum 26th Annual Growth Conference: Checkpoint will present a
company overview on Thursday, March 22, 2018, at 11:50 a.m. EDT at The University Club of New
York in New York City

A live webcast of The Wall Street Investor Forum presentation will be available on the Events page of the
Investors & Media section of Checkpoint’s website: www.checkpointtx.com. An archived replay of the
webcast will be available for approximately 30 days following the presentation.